4-(bromomethyl)-3-methylbenzonitrile | 1247022-11-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-(bromomethyl)-3-methylbenzonitrile
• CAS: 1247022-11-2
• 化学式: C₉H₈BrN
• mdl: MFCD18394364
• 分子量: 210.073
• InChiKey: AFWUDADEHIHOQA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.12
• 重原子数：
  11.0
• 可旋转键数：
  1.0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.222
• 拓扑面积：
  23.79
• 氢给体数：
  0.0
• 氢受体数：
  1.0

反应信息

• 作为反应物：
  描述：

  4-(bromomethyl)-3-methylbenzonitrile 在 盐酸 、 氯化亚砜 作用下， 以 1,4-二氧六环 、 乙腈 为溶剂， 生成
  参考文献：
  名称：

  Discovery and in Vivo Evaluation of Potent Dual CYP11B2 (Aldosterone Synthase) and CYP11B1 Inhibitors

  摘要：

  Aldosterone is a key signaling component of the renin-angiotensin-aldosterone system and as such has been shown to contribute to cardiovascular pathology such as hypertension and heart failure. Aldosterone synthase (CYP11B2) is responsible for the final three steps of aldosterone synthesis and thus is a viable therapeutic target A series of imidazole derived inhibitors, including clinical candidate 7n, have been identified through design and structure-activity relationship studies both in vitro and in vivo. Compound 7n was also found to be a potent inhibitor of 11 beta-hydroxylase (CYP11B1), which is responsible for cortisol production. Inhibition of CYP11B1 is being evaluated in the clinic for potential treatment of hypercortisol diseases such as Cushing's syndrome.

  DOI：

  10.1021/ml400324c

文献信息

• ALDH2 ACTIVATOR
  申请人：Eisai R&D Management Co., Ltd.

  公开号：US20190231720A1

  公开（公告）日：2019-08-01

  The present invention provides a compound represented by formula ( 1 ): or pharmaceutically acceptable salt thereof, wherein X and Y are the same or different from each other and represent a hydrogen atom, a halogen atom, a C 1-6 alkyl group, or a C 1-6 alkoxy group, wherein the C 1-6 alkoxy group may be substituted with a C 1-6 alkoxy group, and Z and W are the same or different from each other and represent a hydrogen atom, a halogen atom, or a C 1-6 alkyl group.

  本发明提供了一种由下式（1）表示的化合物或其药学上可接受的盐，其中X和Y彼此相同或不同，表示氢原子、卤原子、C1-6烷基或C1-6甲氧基，其中C1-6甲氧基可以被C1-6烷氧基取代，Z和W彼此相同或不同，表示氢原子、卤原子或C1-6烷基。
• [EN] RECEPTOR ANTAGONISTS<br/>[FR] ANTAGONISTES DE RÉCEPTEUR
  申请人：PROXIMAGEN LTD

  公开号：WO2014020351A1

  公开（公告）日：2014-02-06

  N-(4-carbamimidoylphenyl)-amide derivatives having utility in therapy as PAR2 receptor antagonists.

  具有在治疗中有用的PAR2受体拮抗作用的N-(4-氨基甲酰基苯基)-酰胺衍生物。
• [EN] EP2/4 AGONISTS<br/>[FR] AGONISTES DE EP2/4
  申请人：PFIZER

  公开号：WO2010116270A1

  公开（公告）日：2010-10-14

  EP2/4 compounds having improved dual pharmacological activity are described. The uniqueness of using EP2/4 dual agonists resides in their ability to modify both uveoscleral outflow via the ciliary muscle and conventional outflow via trabecular meshwork and Schlemm's canal all in the same treatment paradigm. The compounds can be employed for the treatment of glaucoma and ocular hypertension. Formula (I).

  描述了具有改进的双重药理活性的EP2/4化合物。使用EP2/4双激动剂的独特之处在于它们能够通过睫状肌修改虹膜房和通过网状层和Schlemm氏管的传统流出，这一切都在同一治疗范式中。这些化合物可用于治疗青光眼和眼压增高。公式（I）。
• [EN] AMIDINES AND AMIDINE ANALOGS FOR THE TREATMENT OF BACTERIAL INFECTIONS AND POTENTIATION ANTIBIOTICS<br/>[FR] AMIDINES ET ANALOGUES D'AMIDINE POUR LE TRAITEMENT D'INFECTIONS BACTÉRIENNES ET D'ANTIBIOTIQUES DE POTENTIALISATION
  申请人：UNIV GEORGIA STATE RES FOUND

  公开号：WO2019241566A1

  公开（公告）日：2019-12-19

  Compounds and methods for the treatment of a bacterial infection or the potentiation of an antibiotic in treating a bacterial infection are described herein.

  本文描述了用于治疗细菌感染或增强抗生素治疗细菌感染的化合物和方法。
• ALDH2 activator
  申请人：Eisai R&D Management Co., Ltd.

  公开号：US10406126B2

  公开（公告）日：2019-09-10

  The present invention provides a compound represented by formula (1): or pharmaceutically acceptable salt thereof, wherein X and Y are the same or different from each other and represent a hydrogen atom, a halogen atom, a C1-6 alkyl group, or a C1-6 alkoxy group, wherein the C1-6 alkoxy group may be substituted with a C1-6 alkoxy group, and Z and W are the same or different from each other and represent a hydrogen atom, a halogen atom, or a C1-6 alkyl group.

  本发明提供了一种由式（1）表示的化合物： 或其药学上可接受的盐，其中 X 和 Y 彼此相同或不同，代表氢原子、卤素原子、C1-6 烷基或 C1-6 烷氧基，其中 C1-6 烷氧基可被 C1-6 烷氧基取代，以及 Z 和 W 彼此相同或不同，代表氢原子、卤素原子或 C1-6 烷基。